Search research articles
Contact Us
Filters
Showing results (241-250 of 251) with videos related to
Page
of 26
Sort By:
Haematologica
|
March 9, 2023
Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 study
Corentin Orvain, Sylvain Chantepie, Xavier Thomas, et al.
Leukemia
|
March 31, 2022
RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia
Justine Decroocq, Rudy Birsen, Camille Montersino, et al.
NEJM Evidence
|
June 24, 2025
Intermediate-Dose Cytarabine as Postinduction AML Therapy
Mathilde Hunault, Cécile Pautas, Sarah Bertoli, et al.
The Lancet. Oncology
|
August 4, 2015
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
Farhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2017
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents
Sophie Park, Jean-François Hamel, Andrea Toma, et al.
European Journal of Haematology
|
March 25, 2021
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial
Anne Bouvier, Jean-François Hamel, Jacques Delaunay, et al.
Blood
|
May 21, 2026
Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy
Nicolas Duployez, Romane Joudinaud, Augustin Boudry, et al.
The Journal of Experimental Medicine
|
March 24, 2021
Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
Lucille Stuani, Marie Sabatier, Estelle Saland, et al.
Blood
|
September 15, 2020
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Geoffrey L Uy, Ibrahim Aldoss, Matthew C Foster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 25, 2026
Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation
Katharina Fleischhauer, Cristina Toffalori, Federica Cugnata, et al.
Page
of 26
Search research articles
Search
Showing results (241-250 of 251) with videos related to
Sort By:
Page
of 26
Haematologica
|
March 9, 2023
Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 study
Corentin Orvain, Sylvain Chantepie, Xavier Thomas, et al.
Leukemia
|
March 31, 2022
RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia
Justine Decroocq, Rudy Birsen, Camille Montersino, et al.
NEJM Evidence
|
June 24, 2025
Intermediate-Dose Cytarabine as Postinduction AML Therapy
Mathilde Hunault, Cécile Pautas, Sarah Bertoli, et al.
The Lancet. Oncology
|
August 4, 2015
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
Farhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2017
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents
Sophie Park, Jean-François Hamel, Andrea Toma, et al.
European Journal of Haematology
|
March 25, 2021
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial
Anne Bouvier, Jean-François Hamel, Jacques Delaunay, et al.
Blood
|
May 21, 2026
Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy
Nicolas Duployez, Romane Joudinaud, Augustin Boudry, et al.
The Journal of Experimental Medicine
|
March 24, 2021
Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
Lucille Stuani, Marie Sabatier, Estelle Saland, et al.
Blood
|
September 15, 2020
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Geoffrey L Uy, Ibrahim Aldoss, Matthew C Foster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 25, 2026
Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation
Katharina Fleischhauer, Cristina Toffalori, Federica Cugnata, et al.
Page
of 26